30652-22-3

Upstream product

• 100-46-9 benzylamine 
• 127234-68-8 1-benzyl-3-benzyloxy-2-methyl-4(1H)-pyridinone 
• 181647-78-9 3-Methoxymethoxy-2-methyl-pyran-4-one 
• 118-71-8 Maltol 
• 181647-84-7 1-Benzyl-3-methoxymethoxy-2-methyl-1H-pyridin-4-one 

Downstream Products

• 244187-60-8 cis-bis(1-benzyl-3-hydroxy-2-methyl-4-pyridinonato)dioxomolybdenum(VI) 
• 919366-37-3 (E)-1-benzyl-2-methyl-3-[2-(pyridin-3-yl)vinyl]-4-pyridone 
• 919366-36-2 C₁₅H₁₅NO 
• 919366-34-0 1-benzyl-2-methyl-4-pyridon-3-yl trifluoromethanesulfonate 

Relevant academic research and scientific papers

Synthesis, Modification, and Biological Evaluation of a Library of Novel Water-Soluble Thiopyridone-Based Organometallic Complexes and Their Unexpected (Biological) Behavior

A series of 16 dinuclear thiopyridone-based organometallics with excellent water solubility, increased stability and remarkable cytotoxicity were synthesized and characterized. The complexes of this work formed dimeric species featuring a double positive charge in polar protic solvents, accounting for their outstanding solubility in aqueous solution. Most of them displayed higher antiproliferative activity than their parental thiomaltol complex, with unexpected cytotoxicity trends depending on the employed metal center, ligand modification, and cell line. Insights into their behavior in biological systems were gathered by means of amino-acid interaction studies, cytotoxicity tests in 3D spheroid models, laser ablation, cellular accumulation measurements, as well as cell cycle experiments.

First insights into the novel class of organometallic compounds bearing a bidentate selenopyridone coordination motif: Synthesis, characterization, stability and biological investigations

A series of seven piano–stool complexes featuring selenopyridones as Se,O-chelating ligands was synthesized and characterized. The resulting complexes bear either a p-cym Ru/Os or Cp* Rh/Ir fragment attached to a bidentate selenopyridone ligand. In accordance with recent findings for closely related thiopyridone complexes, dimerization in protic solvents was observed for these compounds. However, these organometallics revealed surprises regarding stability, as well as biological activity. In contrast to analogous thiopyridone organometallics, some of the synthesized complexes were prone to quick ligand dissociation. However, four examples exhibited sufficient stability in aqueous solution to justify further biological investigations. Therefore, MTT assays were carried out for the stable derivatives in three different cancer cell lines. Cytotoxicity trends based on the utilized metal center of the organometallic moiety were observed and compared to the corresponding thio-analogs.

Synthesis, molecular modelling and biological studies of 3-hydroxy-pyrane-4-one and 3-hydroxy-pyridine-4-one derivatives as HIV-1 integrase inhibitors

Background: Despite the progress in the discovery of antiretroviral compounds for treating HIV-1 infection by targeting HIV integrase (IN), a promising and well-known drug target against HIV-1, there is a growing need to increase the armamentarium against

Altering pyridinone N-substituents to optimise activity as potential prodrugs for Alzheimer's disease

Selective design modifications of specifically substituted 3-hydroxy-4(1H)-pyridinones show possibly advantageous ring freedom while maintaining metal-binding ability and antioxidant capacity, moving toward an efficient potential treatment for Alzheimer's disease.

4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI

Bacterial FAS provides essential fatty acids for use in the assembly of key cellular components. Among them, FabI is an enoyl-ACP reductase which catalyzes the final and rate-limiting step of bacterial FAS. It is a potential target for selective antibacterial action, because it shows low overall sequence homology with mammalian enzymes. Until today, various compounds have been reported as inhibitors of bacterial FabI-inhibitory compounds. To discover novel small-molecular FabI inhibitors, we initially screened our compound library for inhibitory activity toward FabI of Escherichia coli. And discovered 4-pyridone derivatives as a lead compound. Structure optimization studies yielded 4-pyridone derivatives 7n having strong FabI-inhibitory and antibacterial activities against Staphylococcus aureus. There have been no reports concerning 4-pyridone derivatives as FabI inhibitor.

Inhibition of Trypanosoma cruzi epimastigotes in vitro by iron chelating agents

The relative effectiveness of 20 iron chelating agents in suppressing the growth and multiplication of Trypanosoma cruzi epimastigotes has been examined in vitro. 1,2-Dimethyl-3-hydroxypyrid-4-one (L1) and several of its newly synthesized N-substituted analogs containing hydrophobic substituents were significantly more effective than deferoxamine, even though they possess only two donor sites for iron(III) while deferoxamine has six. Analogs with hydrophilic substituents were uniformly less active than L1 itself. Variations in effectiveness as the polarity of the compounds is varied indicate that the ability to cross the cellular membrane is of critical importance in the determination of the in vitro trypanocidal activity of iron(III) chelating agents. A group of four tris(2-aminoethyl)amine based tris-imines were also screened, all of which had poor activity (0-28% inhibition). Among the other iron(III) chelating agents which showed a relatively high level of activity at 50 and 100 μg/ml were salicylhydroxamic acid (70 and 73% inhibition) and hydroxyurea (42 and 52% inhibition). N,N'-Di(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid and acetohydroxamic acid exhibited only slight activity at 50 and 100 μg/ml. The best of these iron(III) chelating agents were as effective against the epimastigote form at both 50 and 100 μg/ml (74-82% inhibition) as benznidazole (81% inhibition), the drug currently used in the clinic.

3-Hydroxy-4-pyrones as precursors of 4-methoxy-3-oxidopyridinium ylides. An expeditious entry to highly substituted 8-azabicyclo[3.2.1]octanes

3-Hydroxy-4-pyridones, which are easily prepared from commercially available 3-hydroxy-4-pyrones, can be readily transformed into 4-methoxy-3-oxidopyridinium ylides by treatment with methyl trifluoromethanesulfonate and subsequent deprotonation with a non-nucleophilic base. These ylides are capable of undergoing cycloaddition to several electron-deficient alkenes, thus allowing the synthesis of highly functionalized azabicyclo[3.2.1]octane moieties. The rich substitution patterns of these frameworks might allow their divergent conversion to a variety of natural and non-natural tropane alkaloids.

Technetium-99m complexes with N-substituted 3-hydroxy-4-pyridinones

Disclosed are cationic complexes of Tc-99m and ligands having the structure: STR1 wherein: R1 is hydrogen or is selected from the group consisting of C1 to C20 alkyl; C3 to C12 cycloalkyl; C7/su